Sleep medications increase dementia risk in white population but the type and quantity of the medication may be factors in explaining the higher risk, suggests the findings of a recent study.
It follows previous work that shows that the Black population have a higher likelihood than whites of developing Alzheimer’s, the most common type of dementia, and that they have different risk factors and disease manifestations. The final corrected draft of the study publishes in the Journal of Alzheimer’s Disease on January 31, 2023.
In the study, approximately 3,000 older adults without dementia, who lived outside of nursing homes, were enrolled in the Health, Aging and Body Composition study and followed over an average duration of nine years. Their average age was 74; 42 per cent were Black and 58 per cent were white.
During the study, 20 per cent developed dementia. White participants who “often” or “almost always” took sleep medications had a 79 per cent higher chance of developing dementia compared to those who “never” or “rarely” used them. Among Black participants – whose consumption of sleep aids was markedly lower – frequent users had a similar likelihood of developing dementia than those who abstained or rarely used the medications.
Higher-income Blacks May Be Less Likely to Get Dementia
“Differences may be attributed to socioeconomic status,” said first author Yue Leng, PhD, of the UCSF Department of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences. “Black participants who have access to sleep medications might be a select group with high socioeconomic status and, thus, greater cognitive reserve, making them less susceptible to dementia.
“It’s also possible that some sleep medications were associated with a higher risk of dementia than others.”
The researchers found that whites, at 7.7 per cent, were three times as likely as Blacks, at 2.7 per cent, to take sleep medications often, five to 15 times a month, or almost always, 16 times a month to daily. Whites were almost twice as likely to use benzodiazepines, like Halcion, Dalmane and Restoril, prescribed for chronic insomnia.
Whites were also 10 times as likely to take trazodone, an antidepressant known by the trade names of Desyrel and Oleptro, which may also be prescribed as a sleep aid. And they were more than seven times as likely to take “Z-drugs,” such as Ambien, a so-called sedative-hypnotic.
While the future study may offer clarity on the cognitive risks or rewards of sleep medications and the role that race may play, patients with poor sleep should hesitate before considering medications, according to Leng.
“The first step is to determine what kind of sleep issues patients are dealing with. A sleep test may be required if sleep apnea is a possibility,” she said. “If insomnia is diagnosed, cognitive behavioural therapy for insomnia (CBT-i) is the first-line treatment. If medication is to be used, melatonin might be a safer option, but we need more evidence to understand its long-term impact on health.” (ANI)